Similar tumor responses were also reported with the humanized anti-GD2 antibody naxitamab co-administered with GM-CSF in a Phase 1/2 study in patients with primary or secondary refractory neuroblastoma [22]. This evidence concerns the gene CSF2 and neuroblastoma.